Progressive Supranuclear Palsy (PSP)
Conditions
Brief summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Interventions
DRUGABBV-8E12
Solution for infusion
Sponsors
AbbVie
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject completed Study C2N-8E12-WW-104 (NCT02494024) * Subject was not eligible to enroll in Study M15-562 (NCT02985879)
Exclusion criteria
* Subject weighs less than 35 kg at screening * Subject has any contraindication or inability to tolerate brain MRI * Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | From first dose of study drug to 20 weeks after last dose of study drug (up to 2 years, 5 months) | Adverse events and serious adverse events will be monitored throughout the dosing period and for approximately 20 weeks after the last dose. |
Countries
United States
Outcome results
None listed